I would think it will take more than clever spin this time. Investors from previous cr seem to be still more than 50% down from 1.30 where they raised 28 million or something like that. Who knows if they were the ones making money by shorting for the last 2 years or so. I would assume they will need a similar amount again if any of the current pipeline of potential treatments are to reach a meaningfull point. Also an interesting position as the family seem to hold a very large percentage of the company. If they try to raise from shareholders they will need to find a large amount of cash to cover their percentage or avoid dilution. I am wondering if burns trial may have actually produced some good results and maybe somehow they can license that out to a pharma or large investor in return for a significant placement at current price or higher? They always maintained sepsis and now UTI were primary tagets. I certainly think the main holders will be keen to minimise new shares on issue and dilution while ensuring there is cash for the forseeable future. 30 million for some sort of rights or license to surface treatments would be a good option. Hopefully they don't just have to give a huge discount like many others.
RCE Price at posting:
56.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)